Bei Akademie registrieren
AbbVie Inc., US00287Y1091

AbbVie stock adds Nxera IBD candidate to immunology pipeline

Published on 11/09/2026 at 16:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock gains worldwide rights to an investigational IBD program. The Phase 1 asset still faces clinical and regulatory milestones.

Pipeline Deal Adds Immunology Optionality

  • AbbVie obtained exclusive worldwide rights to Nxera Pharma's investigational NXE0033744 for inflammatory bowel disease.
  • The oral EP4 receptor agonist has completed Phase 1, but further clinical development and regulatory decisions remain ahead.
  • Nxera will receive a USD 100 million upfront payment and may earn up to USD 1.37 billion in development and commercial milestones.
AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.
AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

AbbVie expanded its immunology pipeline on Wednesday, November 4, by taking exclusive worldwide rights to Nxera Pharma's investigational NXE0033744 for inflammatory bowel disease. The terms were announced in a Nxera Pharma release.

New Asset Remains Investigational

NXE0033744 is an oral EP4 receptor agonist designed to act locally in the gastrointestinal tract. Nxera said its completed Phase 1 program supported a gut-selective profile and target engagement. The candidate is not approved, so additional clinical evidence and regulatory decisions will determine whether the program can progress.

Nxera will receive USD 100 million upfront and is eligible for up to USD 1.37 billion in development and commercial milestone payments, plus tiered royalties on net sales. The transaction remains subject to customary antitrust clearances, including review under the Hart-Scott-Rodino Act.

What Investors Watch Next

The agreement adds another potential immunology asset as AbbVie develops its portfolio beyond established products. The next material signals are the timing and design of further clinical work, efficacy data in inflammatory bowel disease and any regulatory filing.

AbbVie stock traded at 259.40 euros on Lang & Schwarz at 16:09 CET on Monday, November 9, 2026, 0.12 percent below the Xetra close of Friday, November 6, at 259.70 euros. The quote was 1.44 percent below the 263.20 euros recorded at 08:33 CET in the previous AbbVie report.

AbbVie Inc. stock facts

  • Company: AbbVie Inc.
  • ISIN: US00287Y1091
  • Xetra ticker: 4AB.DE
  • Sector: Healthcare
  • Lang & Schwarz price: 259.40 euros at 16:09 CET on November 9, 2026
  • Xetra close: 259.70 euros on November 6, 2026

The S&P 500 provides the broader US market backdrop for pharmaceutical shares.

More news and analyses on AbbVie stock will track clinical, regulatory and commercial developments.

Disclaimer...
en | US00287Y1091 | ABBVIE INC. | boerse | 70481843 | bgmi